Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

Q-Plex™ Human IL-8

  • Regulatory status:RUO
  • Type:Singleplex Assays
  • Other names:IL-8, Monocyte-derived neutrophil chemotactic factor, T-cell chemotactic factor, Neutrophil-activating protein 1, Granulocyte chemotactic protein 1
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


466749HU 96 wells (1 kit)
PubMed Product Details
Technical Data

Cat # changed from RQS466749HU to 466749HU

Type

Singleplex Assays

Applications

Serum, Plasma, Cell culture supernatant

Sample Requirements

50 µl/well

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date.

Calibration Range

2000–2.74 pg/ml

Limit of Detection

1.8 pg/ml

Summary

Features

  • For research use only
  • Detection Method: Chemiluminescent
  • This kit is validated for use with plasma, serum, and cell culture supernates

Research topic

Cytokines and chemokines and related molecules, Immune Response, Infection and Inflammation, Oncology, Sepsis

Summary

The Q-Plex™ Human IL-8 Kit is a fully quantitative ELISA. The assay measurement is achieved by placing two spots consisting of capture antibodies in a defined array to the bottom of each well of a 96-well plate. Along with the assay spots, there is one positive control spot for assuring proper assay procedure and for software overlay placement. High quality reagents help ensure the accuracy and precision of your results.

Using less than 50 μL of sample per well, up to 80 samples can be assayed for a single assay within 2.5 hours. The array design of the singleplex kit, allows the user to have intra-well replicates for additional statistical data. The Q-Plex™ Human IL-8 ELISA provides researchers an easy to use and cost effective means of generating data for each sample.

Summary References (20)

References to Interleukin-8

  • Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992 Jul 27;307 (1):97-101
  • Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 2005 Apr;7 (2):122-33
  • Burrows SD, Doyle ML, Murphy KP, Franklin SG, White JR, Brooks I, McNulty DE, Scott MO, Knutson JR, Porter D, et al. Determination of the monomer-dimer equilibrium of interleukin-8 reveals it is a monomer at physiological concentrations. Biochemistry. 1994 Nov 01;33 (43):12741-5
  • DeForge LE, Fantone JC, Kenney JS, Remick DG. Oxygen radical scavengers selectively inhibit interleukin 8 production in human whole blood. J Clin Invest. 1992 Nov;90 (5):2123-9
  • DeForge LE, Preston AM, Takeuchi E, Kenney J, Boxer LA, Remick DG. Regulation of interleukin 8 gene expression by oxidant stress. J Biol Chem. 1993 Dec 05;268 (34):25568-76
  • Donnelly SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC, Grant IS, Pollok AJ, Haslett C. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet. 1993 Mar 13;341 (8846):643-7
  • Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science. 1991 Sep 13;253 (5025):1278-80
  • Huang GT, Potente AP, Kim JW, Chugal N, Zhang X. Increased interleukin-8 expression in inflamed human dental pulps. Oral Surg Oral Med Oral Pathol. 1999 Aug;88 (2):214-20
  • Kauma S, Takacs P, Scordalakes C, Walsh S, Green K, Peng T. Increased endothelial monocyte chemoattractant protein-1 and interleukin-8 in preeclampsia. Obstet Gynecol. 2002 Oct;100 (4):706-14
  • Lemster BH, Carroll PB, Rilo HR, Johnson N, Nikaein A, Thomson AW. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin Exp Immunol. 1995 Feb;99 (2):148-54
  • Livaditi O, Kotanidou A, Psarra A, Dimopoulou I, Sotiropoulou C, Augustatou K, Papasteriades C, Armaganidis A, Roussos C, Orfanos SE, Douzinas EE. Neutrophil CD64 expression and serum IL-8: sensitive early markers of severity and outcome in sepsis. Cytokine. 2006 Dec;36 (5-6):283-90
  • Matsushima K, Oppenheim JJ. Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF. Cytokine. 1989 Nov;1 (1):2-13
  • Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Phy. 2003 Apr;284 (4):L566-77
  • Mukaida N, Harada A, Yasumoto K, Matsushima K. Properties of pro-inflammatory cell type-specific leukocyte chemotactic cytokines, interleukin 8 (IL-8) and monocyte chemotactic and activating factor (MCAF). Microbiol Immunol. 1992;36 (8):773-89
  • Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T, Matsushima K. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem. 1994 May 06;269 (18):13289-95
  • Paolini JF, Willard D, Consler T, Luther M, Krangel MS. The chemokines IL-8, monocyte chemoattractant protein-1, and I-309 are monomers at physiologically relevant concentrations. J Immunol. 1994 Sep 15;153 (6):2704-17
  • Sharma A, Satyam A, Sharma JB. Leptin, IL-10 and inflammatory markers (TNF-alpha, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women. Am J Reprod Immunol. 2007 Jul;58 (1):21-30
  • Teles RP, Likhari V, Socransky SS, Haffajee AD. Salivary cytokine levels in subjects with chronic periodontitis and in periodontally healthy individuals: a cross-sectional study. J Periodontal Res. 2009 Jun;44 (3):411-7
  • Tsai CC, Ho YP, Chen CC. Levels of interleukin-1 beta and interleukin-8 in gingival crevicular fluids in adult periodontitis. J Periodontol. 1995 Oct;66 (10):852-9
  • Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008 Nov 01;14 (21):6735-41
Related Products Docs